Towards evidence-based combinations of approved and novel cancer drugs

Publicaciones

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Autores: Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago-Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam , Tomer-Meir Salame, Moshit Lindzen, Yosef Yarden
Publicado en: EMBO Molecular Medicine, 2021, ISSN 1757-4684
Editor: Chichester Wiley Europe
DOI: 10.15252/emmm.202013144

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

Autores: Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee, Benny Zhitomirsky, Yaara Oren, Sara Oster, Moshit Lindzen, Saptaparna Mukherjee, Rainer Will, Soma Ghosh, Arturo Simoni-Nieves, Aakanksha Verma, Rishita Chatterjee, Simone Borgoni, Welles Robinson, Sanju Sinha, Alexander Brandis, D. Lucas Kerr, Wei Wu, Arunachalam Sekar, Suvendu Giri, Youngmin Chung, Diana Drago-Garcia, Brian P. Danysh, Matt
Publicado en: Cancer Discovery, 2022, Página(s) 2666–2683, ISSN 2159-8290
Editor: American Association for Cancer Research
DOI: 10.1158/2159-8290.cd-22-0111

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

Autores: D. Romaniello, L. Mazzeo, M. Mancini, I. Marrocco, A. Noronha, M. Kreitman, S. Srivastava, S. Ghosh, M. Lindzen, T.M. Salame, A. Onn, J. Barr, Y. Yarden
Publicado en: Clinical Cancer Research, Edición November 15, 2018, 2018, Página(s) 5610-5621, ISSN 1557-3265
Editor: AACR
DOI: 10.1158/1078-0432.ccr-18-0450

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Autores: Maicol Mancini, Hilah Gal, Nadège Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick GA Burton, Lee Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden
Publicado en: EMBO Molecular Medicine, Edición 10/2, 2018, Página(s) 294-308, ISSN 1757-4676
Editor: John Wiley & Sons Ltd.
DOI: 10.15252/emmm.201708076

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Autores: Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, Jeanette Clarissa Kittel, Nadege Gaborit, Gretchen Bergado Baez, Belinda Sanchez, Raya Eilam, Eli Pikarsky, Luis Paz-Ares, Yosef Yarden
Publicado en: Cancers, Edición 12/9, 2020, Página(s) 2394, ISSN 2072-6694
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers12092394

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors

Autores: Yuya Haga , Ilaria Marrocco , Ashish Noronha , Mary Luz Uribe , Nishanth Belugali Nataraj , Arunachalam Sekar , Diana Drago-Garcia, Simone Borgoni, Moshit Lindzen , Suvendu Giri , Stefan Wiemann , Yasuo Tsutsumi , Yosef Yarden
Publicado en: CANCER RESEARCH, 2021, ISSN 0008-5472
Editor: American Association for Cancer Research
DOI: 10.1158/0008-5472.can-20-3555

PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

Autores: Soma Ghosh, Nishanth Bulugali Nataraj, Ashish Noronha, Sushant Patkar, Arunachalam Sekar, Saptaparna Mukherjee, Sabina, Winograd-Katz, Lior Kramarski, Aakanksha Verma, Moshit Lindzen, Diana Drago Garcia, Joseph Green, Galit Eisenberg, Hava Gil-Henn, Arkaprabha Basu, Yan Lender, Shimon Weiss. Moshe oren. Yosef Yarden
Publicado en: Cell Reports, 2021, ISSN 2211-1247
Editor: Cell Press
DOI: 10.1016/j.celrep.2021.109181

Buscando datos de OpenAIRE...

Publicaciones

Compartir esta página

Descargar